TICKERNERD
Menu
ALTALTHealthcare · Biotechnology

ALT Stock Forecast: Altimmune, Inc. Price Predictions for 2026-2027

Last close, 11 Nov 2026
$1.93
−0.52% on the day

The 10 Wall Street analysts covering Altimmune, Inc. hold a median 12-month price target of $17 — +780.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 27 of 100 as at 11 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$377.4M
Ticker Nerd rank
27/ 100
Median analyst target
$17
Analysts covering
10
Revenue$0.0−100.0% y/y
Operating income−$26.2M
Net income−$22.8M
Free cash flow−$24.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.0%
1M
−26.1%
YTD
−46.5%
1Y
−54.9%
From 52W high
−68.8%
From 52W low
0.0%
$1.93
$6.18
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Altimmune, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Nov 2026
27/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
74
Revisions
63
Size
56
Quality
53
Accruals
30
Volatility
29
Momentum
21
Value
20
Issuance
11

Growth (74): Sales and profits are climbing, and climbing faster than before.

Issuance (11): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ALT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00$20.00$25.00$30.00Jan 26Apr 26Jul 26Oct 26ALTHigh $28Median $17Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
9 Buy1 Hold0 Sell
Low $11Median $17High $28

The green dot is the last close — the median target sits +780.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 Sept 2026Evercore ISI GroupMaintainsOutperform$18 → $17
23 Sept 2026Evercore ISI GroupMaintainsOutperform—
22 June 2026Leerink PartnersInitiatesOutperform$10
22 June 2026Leerink PartnersInitiatesOutperform—
18 May 2026HC Wainwright & Co.MaintainsBuy—
14 May 2026CitizensMaintainsMarket Outperform—
16 Mar 2026HC Wainwright & Co.MaintainsBuy—
6 Mar 2026B. Riley SecuritiesMaintainsBuy—
7 Nov 2025CitizensMaintainsMarket Outperform—
20 Oct 2025HC Wainwright & Co.ReiteratesBuy—
10 Oct 2025HC Wainwright & Co.ReiteratesBuy—
13 Aug 2025B. Riley SecuritiesMaintainsBuy—
13 Aug 2025HC Wainwright & Co.ReiteratesBuy—
13 Aug 2025UBSMaintainsBuy—
10 July 2025JMP SecuritiesMaintainsMarket Outperform—
27 June 2025HC Wainwright & Co.ReiteratesBuy—
3 Apr 2025HC Wainwright & Co.ReiteratesBuy—
2 Apr 2025Citizens Capital MarketsReiteratesMarket Outperform—
18 Mar 2025HC Wainwright & Co.ReiteratesBuy$12
14 Mar 2025Citizens Capital MarketsReiteratesMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ALT appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ALT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Nov 2026, Altimmune, Inc. returned −54.9% against +12.4% for the S&P 500, dividends included.

ALT vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Jan 26Apr 26Jul 26Oct 26ALTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Altimmune, Inc. (ALT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.9×

Cheaper than 86% of US stocks

Price / sales
12173.0×

Cheaper than 1% of US stocks

Price / book
0.8×

Cheaper than 75% of US stocks

EV / EBITDA
−0.9×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
−318493.5%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−28.9%

Higher than 27% of US stocks

Return on assets
−17.2%

Higher than 21% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Altimmune, Inc. (ALT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Altimmune, Inc. has a market value of $377.4M and an enterprise value of $87.1M.

  • Revenue in the twelve months to 30 June 2026: $31K. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$91.8M, a −296000.0% net margin.

  • Diluted earnings per share, trailing twelve months: −$0.78.

  • Free cash flow in the twelve months to 30 June 2026: −$76.6M.

  • Shares outstanding: 194.5M.

  • Trailing P/E: −1.9×; forward P/E: −2.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Altimmune, Inc. employs 57 people — $543.9 of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Nov 2026

Data provided by Twelve Data

Peers

ALT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ALTAltimmune, Inc.$377.4M27
CCCCC4 Therapeutics, Inc.$379.5M64
EDITEditas Medicine, Inc.$365.2M71
PEPGPepGen Inc.$364.3M55
FENCFennec Pharmaceuticals, Inc.$363.2M83
RZLTRezolute, Inc.$389.5M36
ALECAlector, Inc.$389.9M96

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Altimmune, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALT news & analysis

Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder

GlobeNewsWire · 9 Nov 2026positive

Altimmune presented late-breaking results from its RECLAIM Phase 2 study of pemvidutide in patients with alcohol use disorder at AASLD The Liver Meeting® 2026. The study reported a significant reduction in heavy drinking days, improvements on other key clinical measures, and generally favorable tolerability.

Why it matters — The reported clinical findings provide ALT watchers with an update on pemvidutide’s progress in alcohol use disorder.

Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026

GlobeNewsWire · 5 Nov 2026positive

Altimmune announced that key data from its RECLAIM Phase 2 trial of pemvidutide in alcohol use disorder were selected for a late-breaking oral presentation at AASLD The Liver Meeting 2026. The presentation will be the first at a scientific conference of data from the multicenter trial.

Why it matters — The conference selection brings attention to clinical-trial data for Altimmune’s pemvidutide program in alcohol use disorder.

Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution

GlobeNewsWire · 27 Oct 2026positive

Altimmune appointed Peter Greenleaf and Alex Howarth to its board of directors. The appointments accompany the company’s transition to late-stage clinical development of pemvidutide as a liver-focused program with multiple potential indications.

Why it matters — ALT watchers may note the board changes as the company moves into a late-stage clinical phase and develops its pemvidutide liver franchise.

Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026

GlobeNewsWire · 19 Oct 2026positive

Altimmune announced that new clinical and preclinical data on pemvidutide will be presented at AASLD The Liver Meeting 2026. The announcement highlights IMPACT Phase 2b findings in MASH showing improvements in liver fibrosis and inflammation with generally favorable gastrointestinal tolerability, alongside preclinical data on alcohol intake.

Why it matters — The presentations will provide ALT watchers with additional clinical and preclinical information about pemvidutide in serious liver diseases.

FAQ

Frequently asked questions about ALT stock

What is the ALT stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Altimmune, Inc. have a median 12-month price target of $17, with estimates ranging from $11 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALT stock a buy right now?

Of the 10 analysts covering Altimmune, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Altimmune, Inc. 27 out of 100 across roughly 4,600 US stocks as at 11 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALT?

As at 11 Nov 2026, Altimmune, Inc. ranks 27 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (74 of 100).

Will ALT stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +780.8% from the last close, and Ticker Nerd's factor model ranks Altimmune, Inc. 27 out of 100 as at 11 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALT stock forecast for 2030?

No analyst covering Altimmune, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $28 over the next 12 months.

How has ALT stock performed over the past year?

Altimmune, Inc. returned -54.9% over the 12 months to 11 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Altimmune, Inc. do?

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing peptide-based therapies for obesity, metabolic disorders, and serious liver diseases.

What is the latest news on ALT?

The most recent item we track (GlobeNewsWire, 9 Nov 2026): "Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder". Altimmune presented late-breaking results from its RECLAIM Phase 2 study of pemvidutide in patients with alcohol use disorder at AASLD The Liver Meeting® 2026. The study reported a significant reduction in heavy drinking days, improvements on other key clinical measures, and generally favorable tolerability.

Company

About Altimmune, Inc.

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing peptide-based therapies for obesity, metabolic disorders, and serious liver diseases. The company’s lead product candidate, pemvidutide, is a dual GLP-1 and glucagon receptor agonist being studied for conditions such as metabolic dysfunction-associated steatohepatitis, alcohol use disorder, alcohol-associated liver disease, and obesity. Altimmune is also developing HepTcell, an immunotherapeutic program designed for chronic hepatitis B. Through these programs, Altimmune operates at the intersection of metabolic medicine, hepatology, and immunotherapy, with a pipeline aimed at addressing complex diseases that currently have limited treatment options. The company is headquartered in Gaithersburg, Maryland.

CEO Mr. Jerome Benedict Durso · 57 employees · United States · https://altimmune.com